QCM Cayman’s Ionis Pharmaceuticals IONS Stock Holding History

QCM Cayman’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-5,221	Closed	-$211K	–	319
2016 Q1	$211K	Buy	+5,221	New	+$212K	0.14%	129

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

QCM Cayman's IONS Position: Q2 2016 in Review

QCM Cayman sold out of Ionis Pharmaceuticals (IONS) in Q2 2016, closing a stake of 5,221 shares — an estimated $211K sold.

QCM Cayman first reported a position in IONS in Q1 2016 and held it in 1 quarter. The position peaked at $211K in Q1 2016. 282 funds tracked by Wall St. Rank hold IONS as of Q2 2016.

QCM Cayman reported no remaining Ionis Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
QCM Cayman sold 5,221 Ionis Pharmaceuticals shares in Q2 2016, an estimated $211K.
QCM Cayman first reported a position in Ionis Pharmaceuticals in Q1 2016 and held it in 1 quarter.
QCM Cayman's Ionis Pharmaceuticals position peaked at $211K in Q1 2016.
282 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2016.

Based on QCM Cayman's 13F filing for Q2 2016, filed 15 Aug 2016.